Products for Research Use Only
RegisterLogin

Purvalanol A

CAT: 0804-HY-18299A-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18299A-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively.
CAS Number
212844-53-6
Product Name Alternative
NG-60
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; Autophagy; CDK
Type
Reference compound
Related Pathways
Apoptosis; Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Purvalanol-A.html
Concentration
10mM
Purity
98.61
Solubility
DMSO : ≥ 50 mg/mL|Ethanol : 10 mg/mL (ultrasonic)
Smiles
CC([C@@H](NC1=NC(NC2=CC=CC(Cl)=C2)=C3N=CN(C(C)C)C3=N1)CO)C
Molecular Formula
C19H25ClN6O
Molecular Weight
388.89
Precautions
H302, H315, H319, H335
References & Citations
[1]Gray NS, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281 (5376) :533-8.|[2]Bain J, et al. The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371 (Pt 1) :199-204.|[3]Villerbu N, et al. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002 Feb 20;97 (6) :761-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK1; CDK2; CDK4; CDK5

Alternative Products

CatalogName
T2059-01Purvalanol A

Popular Products